CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.
about
CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritisChemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte traffickingA novel nonhuman primate model for influenza transmissionCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusThe immunology of influenza virus-associated bacterial pneumoniaTherapeutic inflammatory monocyte modulation using immune-modifying microparticlesMesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza.Innate immune sensing and response to influenza.Collectins, H-ficolin and LL-37 reduce influence viral replication in human monocytes and modulate virus-induced cytokine production.Adapting global influenza management strategies to address emerging viruses.Newer influenza antivirals, biotherapeutics and combinations.Expression of suppressor of cytokine signaling 1 (SOCS1) impairs viral clearance and exacerbates lung injury during influenza infection.Into the eye of the cytokine storm.Plasmacytoid dendritic cell depletion leads to an enhanced mononuclear phagocyte response in lungs of mice with lethal influenza virus infectionTRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection.The cytokine storm of severe influenza and development of immunomodulatory therapyNf1+/- monocytes/macrophages induce neointima formation via CCR2 activation.Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza S. aureus pneumonia.Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cellsCD11c⁺ cells primed with unrelated antigens facilitate an accelerated immune response to influenza virus in mice.Immunomodulatory therapy for severe influenza.Targeting the "cytokine storm" for therapeutic benefit.Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections.The role of lung dendritic cell subsets in immunity to respiratory viruses.Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production.The inflammatory response triggered by Influenza virus: a two edged sword.Editor's Highlight: CCR2 Regulates Inflammatory Cell Accumulation in the Lung and Tissue Injury following Ozone Exposure.Tumor Necrosis Factor Alpha-Induced Recruitment of Inflammatory Mononuclear Cells Leads to Inflammation and Altered Brain Development in Murine Cytomegalovirus-Infected Newborn Mice.Protective role of LGP2 in influenza virus pathogenesis.Distinct functions of CXCR4, CCR2, and CX3CR1 direct dendritic cell precursors from the bone marrow to the lung.Interleukin-22 immunotherapy during severe influenza enhances lung tissue integrity and reduces secondary bacterial systemic invasion.Surviving Deadly Lung Infections: Innate Host Tolerance Mechanisms in the Pulmonary System.Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfectionRole of Inflammatory Risk Factors in the Pathogenesis of
P2860
Q24701793-5EFD1DF4-4965-4C7F-9821-B64386D7BF84Q27013008-1CC6D11B-9630-4807-B5DD-CF61E7D8726FQ27302967-B755C89F-12C3-4E2A-9C0D-F07EBD1DC2C1Q28084005-D5386E26-0CB0-4E51-AB94-3DEC3F820C44Q28084679-45F3F6FA-B284-49F5-8B30-0DEB22089C17Q28305924-A8D40C80-4710-4EB7-8C24-B04DBE177DA5Q30353064-FA9236B6-1E33-4800-823D-5BCA0E6CA8D8Q30365302-B60D3DA6-EB20-414C-96F1-AB0D53EFFC38Q30395313-F54B2400-191F-4132-A054-0DABA969C4E4Q30431093-63BA1C4A-DD91-4B34-84F2-6F758AF0DDDFQ30456363-44F06F2D-8EE0-46C8-A857-EF18292D1287Q35513704-D98DA43A-D422-4A95-923E-17145AB5C69DQ35804633-F5255970-D285-40F3-86E1-69E4416D968CQ36010636-CA0B12B1-52E6-4E28-8601-FCF98F6FB6E6Q36078577-653A32F2-31B6-44B6-BCDA-0DDCEE9AFAA1Q36459143-AC22A5B6-0677-479B-BEAB-316B6A8BB38FQ36608863-30D1FEB4-038C-4B6C-934B-6E1ED85EE5AAQ37197883-2199D6E8-0C1D-46DD-B5A6-187634B580C8Q37403787-D3B02AD0-655B-4BB4-AB8B-D858AAFD2328Q37588815-C525DEEE-2DEC-4E85-BDE6-5BAC0E36C6C4Q37910249-FBE9A058-F197-4FDE-A7FD-479B2E9D61D4Q38071254-04072950-A5AD-4C6A-B328-22888AF03C03Q38095347-C57A4497-835A-46A5-94DB-536463D18481Q38129081-5A26FF95-9B2B-4FBE-97F2-29E5EDE49F6EQ38693815-D3A6D227-A178-4718-B55F-222221569B5AQ38981754-19C65506-AC0D-4451-BA0A-B908E68DC0C3Q39193693-8C4DA049-6BBC-4806-94C4-690115784023Q40358106-C44E09F8-B387-4456-B85E-8903680A17C1Q42239259-85321C15-7EC5-4B3C-98B6-947B60452E6CQ51157830-041D9121-B93B-49A0-BFDE-C03F4B43FDA9Q52691346-109E4C83-CE96-4238-AD5C-733F0140AA23Q55514867-4FA70330-A553-43C9-815D-AA219F340F16Q58106783-5F87BFDB-FFA6-44B0-AE27-F2044454F5A1Q58586401-C24465ED-C22E-48DB-9AC6-8B714DA06578
P2860
CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@en
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@nl
type
label
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@en
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@nl
prefLabel
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@en
CCR2-antagonist prophylaxis re ...... al during influenza infection.
@nl
P2093
P2860
P356
P1476
CCR2-antagonist prophylaxis re ...... val during influenza infection
@en
P2093
Brian Donghoon Kang
Elizabeth Ramsburg
Kaifeng Lisa Lin
Shari Sweeney
P2860
P304
P356
10.4049/JIMMUNOL.1001002
P407
P577
2010-11-22T00:00:00Z